comparemela.com

Page 5 - Azn Ln News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pfizer s Obesity Pill Disappointed Biotech Rivals Are Rubbing Their Hands

Pfizer expects the market for new obesity pills to be $90 billion per year. Lilly, Novo, and many biotechs hope to claim chunks of it.

United statesEli lillyRoche holdingannouncedChris shibutaniJay olsonJosh nathan kazisGoldman sachsNovo nordiskTerns pharmaceuticalsViking therapeuticsStructure therapeuticsCarmot therapeuticsArticle normalBiotechnology servicesAgricultural machineryHealthcare life sciences

AstraZeneca Launches Health-Tech Business Evinova -- Update

By Michael Susin AstraZeneca said it has launched Evinova, a separate health-tech business to offer its knowledge of clinical-trial design and study.

Michael susinArticle normalBiotechnology servicesHealthcare life sciencesNew products servicesCorporate industrial newsProducts servicesContent typesFactiva filtersC amp ampe industry news filterAzn lnUk aznNew productsIndustrial newsLife sciences

Pharma Is Out of Favor 5 Drug Stocks With Room to Grow

Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.

Bristol myers squibbEli lillyPearl riverArticle normalAgricultural machineryHealthcare life sciencesIndustrial goodsFinancial performanceCorporate industrial newsPolitical general newsPhysical mental fitnessLiving lifestyleWeight managementContent typesFactiva filtersC amp ampe industry news filter

AstraZeneca Agrees on Licensing Deal for Obesity Treatment

By Joe Hoppe AstraZeneca said it has entered an exclusive agreement with Eccogene, licensing the latter's ECC5004 product for treating conditions such as.

Joe hoppeArticle normalBiotechnology servicesHealthcare life sciencesPolitical general newsSociety communityMedical conditionsSocial issuesAzn lnUk aznGeneral newsLife sciences

AstraZeneca PLC 3Q EPS 88c

By Ian Walker AstraZeneca raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines despite a lower.

Ian walkerArticle normalBiotechnology servicesHealthcare life sciencesFinancial performanceEarnings projectionsCorporate industrial newsContent typesFactiva filtersC amp ampe industry news filterAzn lnUk aznIndustrial newsLife sciences

vimarsana © 2020. All Rights Reserved.